Toxoplasmosis is a parasitic disease of great importance to public health. Each year more than 3,000 infants are born in the United States with congenital toxoplasmosis infection, and many immunocompromised persons with latent infections suffer lethal recurrences of toxoplasmosis infection. Indeed, toxoplasmosis of the CNS has been recognized as one of the manifestations of the acquired immune deficiency syndrome, and many cases have been reported. In the uncompromised host, the most common clinical manifestation of infection is lymphadenopathy that usually resolves spontaneously, although complications (namely, chorioretinitis, myocarditis, hepatitis, and pneumonitis) can occur.1 In infants infected in utero, the classic tetrad of chorioretinitis, hydrocephalus, intracerebral calcification, and convulsions may appear in the severe case; in the inapparent case, damage may be delayed. Early diagnosis and treatment may prevent sequelae in these infants.2,3
Also see p 53.
Serologic surveys have determined that about 50% of the US population has been